RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation

Non-small cell lung cancer (NSCLC) patients with EGFR mutations initially respond well to EGFR tyrosine kinase inhibitors (TKIs) but eventually exhibit acquired or innate resistance to the therapies typically due to gene mutations, such as EGFR T790M mutation or a second mutation in the downstream p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Dis
Main Authors: Cho, Jung Hee, You, Yeon-Mi, Yeom, Y I, Lee, Dong Chul, Kim, Bo-Kyung, Won, Misun, Cho, Byoung Chul, Kang, Minho, Park, Seulki, Yang, Suk-Jin, Kim, Jang Seong, Kim, Jung-Ae, Park, Kyung Chan
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5964247/
https://ncbi.nlm.nih.gov/pubmed/29789542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-018-0651-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados